The National Eye Institute (NEI) seeks research co-development partners and/or licensees for an automatic deep learning-based algorithm to detect and quantitate ellipsoid zone (EZ) loss in Spectral Domain Optical Coherence Tomography (SD-OCT) images.
The National Cancer Institute is seeking research co-development partners and licensing collaborators to accelerate the development and commercialization of innovative bifunctional antibody fusion molecules designed to activate and expand engineered TCR-expressing cells, advancing next-generation cancer immunotherapies.
Traf3ip2-/- C57/BL6 mice are a genetically modified mouse model in which the Traf3ip2 gene, responsible for encoding the CIKS adaptor protein essential for IL-17 cytokine signaling, has been disrupted. These mice offer a robust platform for research in autoimmune and inflammatory diseases, as well as potential applications in cancer studies. By eliminating IL-17 signaling and cross-interactions with other pathways, they provide a unique opportunity for drug discovery and proof-of-principle studies, shedding light on disease mechanisms and therapeutic development.
The "Multiplexed Nanoparticle Platform for Broad-Spectrum Coronavirus Vaccination" represents a cutting-edge approach in the realm of immunization technology. This innovative platform utilizes meticulously engineered nanoparticles, comprised of self-assembling proteins, to present the coronavirus's distinctive spike proteins to the immune system. These nanoparticles are uniquely designed to attach to an immunogenic segment of the virus, ensuring that this critical component is effectively exhibited on the nanoparticle surface.
The inventors have developed an RNA Zika vaccine construct using the self-amplifying mRNA (SAM®) vaccine platform. This technology combines the GSK SAM mRNA delivery vector system with the VRC’s Zika proteins to optimize immune responses against Zika virus, with the ultimate goal of preventing infection. The vaccine is designed to elicit strong and durable immune responses, potentially offering a promising approach to combat Zika virus disease. The current development stage of this technology is likely in the pre-clinical or early clinical stages of testing.
This technology entails a novel vaccine design against malaria, employing an alphavirus Virus-Like Particle (VLP) system to present a critical epitope from the Plasmodium falciparum circumsporozoite protein (PfCSP). The vaccine targets the junctional region between the N-terminus and the central repeat domain of PfCSP, a segment previously identified as vital for generating protective immunity.
The CIS43 antibody represents a cutting-edge advancement in the fight against malaria, a disease caused by Plasmodium parasites and transmitted by mosquitoes. CIS43 targets the junctional epitope of the Plasmodium falciparum circumsporozoite protein, showing promising efficacy in preventing malaria infection in controlled human infection-based studies. The latest developments have focused on generating improved variants of CIS43 with enhanced protective capabilities.
The technology revolves around an innovative monoclonal antibody-based conditioning regimen for enhancing the engraftment of hematopoietic stem cells during bone marrow transplants. It features a novel antibody-drug conjugate that targets CD117, a marker on stem cells, to enable effective transplantation without the harmful side effects of traditional conditioning methods.
The technology in focus encompasses a novel suite of synthetic peptide immunogens, collaboratively developed by leading institutions, aimed at evoking a robust immune response against HIV-1. This breakthrough harnesses the latest advancements in immunology to craft immunogens that elicit broadly neutralizing antibodies in humans, a significant stride in HIV-1 therapeutic and preventive strategies.
The technology pertains to a novel polymer nanoparticle platform designed for the creation of individualized cancer vaccines. It utilizes a two-component system that combines patient-specific peptide neoantigens with immunostimulants within self-assembling nanoparticles. This approach ensures the targeted delivery of neoantigens to the immune system, enhancing the immune response against cancer cells while avoiding the systemic activation often seen with conventional adjuvants.